AU2003250935A1 - Bile acid derivatives as agonists of the farnesoid x receptor - Google Patents

Bile acid derivatives as agonists of the farnesoid x receptor

Info

Publication number
AU2003250935A1
AU2003250935A1 AU2003250935A AU2003250935A AU2003250935A1 AU 2003250935 A1 AU2003250935 A1 AU 2003250935A1 AU 2003250935 A AU2003250935 A AU 2003250935A AU 2003250935 A AU2003250935 A AU 2003250935A AU 2003250935 A1 AU2003250935 A1 AU 2003250935A1
Authority
AU
Australia
Prior art keywords
farnesoid
agonists
receptor
acid derivatives
bile acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003250935A
Other versions
AU2003250935A8 (en
Inventor
Roberto Pellicciari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003250935A1 publication Critical patent/AU2003250935A1/en
Publication of AU2003250935A8 publication Critical patent/AU2003250935A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
AU2003250935A 2002-07-12 2003-07-11 Bile acid derivatives as agonists of the farnesoid x receptor Abandoned AU2003250935A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2002A001532 2002-07-12
IT2002MI001532A ITMI20021532A1 (en) 2002-07-12 2002-07-12 CHEMICAL COMPOUNDS
PCT/EP2003/007512 WO2004007521A2 (en) 2002-07-12 2003-07-11 Bile acid derivatives as agonists of the farnesoid x receptor

Publications (2)

Publication Number Publication Date
AU2003250935A1 true AU2003250935A1 (en) 2004-02-02
AU2003250935A8 AU2003250935A8 (en) 2004-02-02

Family

ID=30012506

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003250935A Abandoned AU2003250935A1 (en) 2002-07-12 2003-07-11 Bile acid derivatives as agonists of the farnesoid x receptor

Country Status (3)

Country Link
AU (1) AU2003250935A1 (en)
IT (1) ITMI20021532A1 (en)
WO (1) WO2004007521A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392714T3 (en) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroids as Agonists for FXR
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
EP2712617B2 (en) 2004-03-12 2020-11-18 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using Fxr ligands
US7618956B2 (en) 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
JP5292310B2 (en) 2007-01-19 2013-09-18 インターセプト ファーマシューティカルズ， インコーポレイテッド 23-substituted bile acids as TGR5 modulators and methods of use thereof
US8338628B2 (en) * 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
CN105037476B (en) 2008-07-30 2018-06-12 英特塞普特医药品公司 TGR5 conditioning agents and its application method
HUE039171T2 (en) 2008-11-19 2018-12-28 Intercept Pharmaceuticals Inc TGR5 modulators and method of use thereof
CA3028207A1 (en) 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
UA118673C2 (en) * 2013-05-14 2019-02-25 Інтерсепт Фармасутікалз, Інк. 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
BR112016005507B1 (en) 2013-09-11 2023-02-07 Centre National De La Recherche Scientifique (Cnrs) USE OF A FARNESOID X RECEPTOR AGONIST (FXR)
CN104672290B (en) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 A kind of medicine of disease for preventing or treating FXR mediations and its production and use
WO2018153933A1 (en) 2017-02-21 2018-08-30 Genfit Combination of a ppar agonist with a fxr agonist
CN110944635A (en) 2017-03-30 2020-03-31 国家医疗保健研究所 Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
CN111247160B (en) * 2017-11-02 2021-09-28 正大天晴药业集团股份有限公司 Preparation method of cholic acid compound
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
AU2021207253A1 (en) 2020-01-15 2022-06-09 Centre National De La Recherche Scientifique Use of FXR agonists for treating an infection by hepatitis D virus
WO2022152770A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223313B (en) * 1987-10-20 1990-09-19 Gipharmex Spa BILIARY ACID DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IT1229570B (en) * 1989-04-17 1991-09-04 Giuliani Spa FLUORATED DERIVATIVES OF BILIARY ACIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK1392714T3 (en) * 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroids as Agonists for FXR

Also Published As

Publication number Publication date
AU2003250935A8 (en) 2004-02-02
WO2004007521A3 (en) 2004-04-01
WO2004007521A2 (en) 2004-01-22
ITMI20021532A1 (en) 2004-01-12

Similar Documents

Publication Publication Date Title
AU2003250935A1 (en) Bile acid derivatives as agonists of the farnesoid x receptor
AU2004266485A1 (en) Phenoxiacetic acid derivatives
AU2003290700A1 (en) Farnesoid x receptor agonists
AU2003255492A1 (en) Heterocyclic derivatives
AU2003218758A1 (en) Derivatives of 1-phenyl-3-phenylpyrazole as herbicides
AU2003293356A1 (en) Dihydropyridinone derivatives as hne inhibitors
AU2003228485A1 (en) Farnesoid x-activated receptor agonists
AU2003275838A1 (en) Pyrrolidin-2-on derivatives as ep4 receptor agonists
AU2003301129A1 (en) Steroid compositions for intraocular use
AU2003256922A1 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
AU2003231805A1 (en) Purine derivatives as liver x receptor agonists
AU2003301216A1 (en) Novel use of liver x receptor agonists
AU2003205558A1 (en) Thioibotenic acid and derivatives thereof
AU2003287912A1 (en) Dicarboxylic acid derivatives as ppar-agonists
AU2003289910A1 (en) Isophtalic acid derivatives
AU2003205707A1 (en) Method for the preparation of highly branched polypeptides
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003224781A1 (en) Crystalline forms of rabeprazole sodium
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2003245880A1 (en) Process for the preparation of thioalkylamine derivatives
AU2003245703A1 (en) Piperazine derivatives as anti-inflammatory agents
AU2003249491A1 (en) Hyaluronic acid derivatives
AU2003229459A1 (en) Methods of using thiazolidinedithione derivatives
AU2003216503A1 (en) Stable pharmaceutical compositions
AU2003273169A1 (en) 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase